Outer membrane vesicles from Neisseria meningitidis: Effects on cytokine production in human whole blood

Cytokine

Volumn 13, Issue 2, 2001, Pages 91-97

  Mirlashari, Mohammad Reza ^a   Høiby, Ernst Arne ^b   Holst, Johan ^b   Lyberg, Torstein ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Cytokines; Lipopolysaccharide; Neisseria meningitidis; Outer membrane vesicles

Indexed keywords

BACTERIAL VACCINE; BACTERIUM LIPOPOLYSACCHARIDE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; OUTER MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; MEMBRANE VESICLE; NEISSERIA MENINGITIDIS; OUTER MEMBRANE; PRIORITY JOURNAL;

NEISSERIA MENINGITIDIS; OAT MOSAIC VIRUS;

EID: 0035924915     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.2000.0803     Document Type: Article

References (56)

1. The epidemiology of meningococcal disease in Norway 1975-1991
2. An epidemiological, clinical and microbiological follow-up study of incident meningococcal disease cases in Norway
3. Immunologic response of man to group B meningococcal polysaccharide vaccines
4. Production, characterization and control of MenB-Vaccine "Folkehelsa": An outer membrane vesicle vaccine against group B meningococcal disease
5. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway
6. Identification of a novel TNFα from the livers of burned and infected rats
7. Biology of proinflammatory cytokines and their antagonists
8. Complement activation and endotoxin levels in systemic meningococcal disease
9. Bacteremia and compartmentalization of LPS in meningococcal disease
10. Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections
11. Some arguments on early hospital admission and treatment of suspected meningococcal disease cases
12. Two types of mouse helper T cell clones. I. Definition according to profile of lymphokine activities and secreted proteins
13. Gene expression of macrophage inflammatory protein-1α from human blood monocytes and alveolar macrophages is inhibited by interleukin-4
14. Interleukin-4 (IL-4) inhibits secretion of IL-1β, tumor necrosis factor α, and IL-6 by human monocytes
15. Interleukin-10 (IL-10) inhibits nuclear factor κB (NF κB) activation in human monocytes
16. Interleukin-13 effects on activated monocytes lead to novel cytokine secretion profiles intermediate between those induced by interleukin-10 and by interferon-γ
17. Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis
18. Meningococcal endotoxin in lethal septic shock plasma studied by gas chromatography, mass-spectrometry, ultracentrifugation, and electron microscopy
19. Lipopolysaccharide, Lipid A, and liposomes containing lipid A as immunologic adjuvants
20. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin
21. Molecular mechanisms in the compartmentalized inflammatory response presenting as meningococcal meningitis or septic shock
22. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease
23. Endotoxin and meningococcemia
24. Plasma levels of cytokines in primary septic shock in humans: Correlation with disease severity
25. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease
26. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura
27. The complex pattern of cytokines in serum from patients with meningococcal septic shock
28. Interleukin-8 in serum and cerebrospinal fluid from patients with meningococcal disease
29. Cytokines in meningococcal disease
30. Local production of tumor necrosis factor-α, interleukin-1, and interleukin-6 in meningococcal meningitis
31. Imbalance between tumor necrosis factor-alpha and soluble TNF-receptor concentrations in severe meningococcaemia
32. Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia
33. Cellular immune responses to Neisseria meningitidis in children
34. Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: Identification of interleukin-10 as a major functional deactivator of human monocytes
35. Measurement of lipopolysaccharide (endotoxin) in meningococcal protein and polysaccharide preparations for vaccine usage
36. Biphasic production of IL-8 in lipopolysaccharide (LPS)-stimulated human whole blood
37. Interleukin 8 and MCAF: Novel inflammatory cytokines inducible by IL-1 and TNF
38. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils
39. Monokine-induced gene expression of a human endothelial cell-derived neutrophil chemotactic factor
40. IL-1 transcriptionally activates the neutrophil chemotactic factor/IL-8 gene in endothelial cells
41. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF
42. Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways
43. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: The effect of inflammatory agents
44. Tumor necrosis factor (TNF) and interleukin 1 (IL 1) in arthritis
45. Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: Sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13
46. Interleukin 19 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes
47. Production of hybridoma growth factor by human monocytes
48. Differences in the synthesis and kinetics of release of TNF-α, IL-1α, IL-1β from human mononuclear cells
49. A critical role for monocytes and CD14 in endotoxin-induced endothelial cell activation
50. Transforming growth factor-beta and interleukin-10, but not interleukin-4, downregulate procoagulant activity and tissue factor expression in human monocyte-derived macrophages
51. Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide
52. High levels of IL-10 during the initial phase of fulminant meningococcal infections
53. High levels of interleukin 10 in serum are associated with fatality in meningococcal disease
54. Dose-related inflammatory effects of intravenous endotoxin in humans: Evaluation of a new clinical lot of Escherichia coli O:113 endotoxin
55. Adverse events following vaccine or placebo injection in an efficacy trial of an outer membrane vesicle vaccine against group B meningococcal disease in Norwegian secondary schools 1988-1991
56. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine